BPA Call 36C24122A0124-36C24122N0693
Award Date
7/15/22
Potential Completion Date
7/14/23
Potential Value
$9.8K
Federal Agency
Veterans Integrated Service Network 1
Ultimate Awardee
Not listed
PSC Category
Q301 - Reference Laboratory Testing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Seattle, WA 98102, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed price Blanket Purchase Agreement (BPA) call awarded by the Department of Veterans Affairs (VA) to Adaptive Biotechnologies Corporation, doing business as Adaptive, to provide ClonoSEQ minimal residual disease testing services for the Boston and West Haven VA health care systems. The contract has a ceiling value of $95,000.00 and a period of performance through July 2026. Adaptive Biotechnologies is a commercial provider of immune-driven medicine services and products, and...
This is a firm fixed price contract awarded by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) to Adaptive Biotechnologies Corporation, doing business as Adaptive, for ClonoSEQ minimal residual disease testing services. The $165,700 contract has a performance period ending July 14, 2025 and is a call under a larger $828,750 single award blanket purchase agreement (BPA) from the VA's Veterans Integrated Service Network 1 for ClonoSEQ services benefiting VA medical...
This is a $6,000 firm fixed price contract awarded by the Veterans Integrated Service Network 1 (VISN 1) of the Department of Veterans Affairs to Adaptive Biotechnologies Corporation, doing business as Adaptive, to provide ClonoSEQ minimal residual disease testing services. The contract is a call under a $828,750 single award blanket purchase agreement (BPA) with the VA's Veterans Health Administration, with two prior calls totaling $331,500 for ClonoSEQ services at VA medical facilities in...
This is a firm fixed price contract awarded by the Department of Veterans Affairs (VA) to Adaptive Biotechnologies Corporation, doing business as Adaptive, for ClonoSEQ minimal residual disease testing services. The contract, with a ceiling value of $9,750.00, is a call under a $828,750.00 single award blanket purchase agreement held by Adaptive with the VA's Veterans Integrated Service Network 1 for a 5-year ordering period ending in July 2027. The contract supports VA medical facilities in the...
This is a $681,270 firm-fixed-price definitive contract awarded by the Defense Health Agency to Adaptive Biotechnologies Corporation, a for-profit provider of immune-driven medicine services and products based in Seattle, Washington. The contract is for ClonoSEQ FDA-cleared in vitro diagnostic (IVD) testing services, which leverage Adaptive's expertise in advanced genomic sequencing, immunosequencing, and minimal residual disease testing. This contract does not have a set-aside designation,...
This federal contract award was made by the Defense Health Agency to Adaptive Biotechnologies Corporation, a commercial provider of immune-driven medicine services and products based in Seattle, Washington. The $224,250 firm fixed-price purchase order is for Adaptive's ClonoSEQ in-vitro diagnostic test service that has received Food and Drug Administration clearance for detecting blood cancer in patients. The contract has a period of performance through February 27, 2030 and is not set aside for...
This is a $385,920 firm fixed price definitive contract awarded by the Defense Health Agency to Adaptive Biotechnologies Corporation, doing business as Adaptive, to provide the ClonoSEQ Minimal Residual Disease In-Vitro Diagnostic Array for the Department of Pathology at the Walter Reed National Military Medical Center. The contract has a performance period ending on February 28, 2025 and does not have a set-aside designation. Adaptive Biotechnologies is a commercial provider of immune-driven...
This is a firm fixed price purchase order valued at $234,900.00 awarded by the National Institutes of Health (NIH) Clinical Center to Adaptive Biotechnologies Corporation, doing business as Adaptive, with a period of performance ending on September 30, 2024. The contract does not have a set-aside designation. Adaptive Biotechnologies is a commercial provider of immune-driven medicine services and products, including immunosequencing, DNA extraction, and COVID-19 research services for the...
The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases awarded a $14,225.00 firm fixed price purchase order to Adaptive Biotechnologies Corporation, doing business as Adaptive, for immunosequencing extraction services. The contract supports NIH research programs and does not have a set-aside designation. Adaptive has previously provided specialized testing and genomic sequencing services to HHS, the Department...
This federal contract award is for IMMUNOSEQ MMTCRB SERVICE (DEEP), catalog # ISS20001, with a quantity of 16, awarded to Adaptive Biotechnologies Corporation by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the National Institutes of Health (NIH). The contract has a firm fixed price of $16,560.00 and a completion date of July 31, 2025. This is not a set-aside contract. Adaptive Biotechnologies is a for-profit organization that specializes in...